Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs

Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein

(2017) Ariola Bardhi et al.   JOURNAL OF VIROLOGY

Engineering antibody-like inhibitors to prevent and treat HIV-1 infection

(2017) Matthew R. Gardner et al.   Current Opinion in HIV and AIDS

One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells

(2017) Wei Li et al.   Scientific Reports

Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design

(2016) Dennis R. Burton et al.   Annual Review of Immunology

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

(2016) Arend von Stackelberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells

(2015) Julia A.M. Sung et al.   JOURNAL OF CLINICAL INVESTIGATION

Activation and lysis of human CD4 cells latently infected with HIV-1

(2015) Amarendra Pegu et al.   Nature Communications

Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells

(2015) Derek D. Sloan et al.   PLoS Pathogens

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice

(2014) Ariel Halper-Stromberg et al.   CELL

Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART

(2014) Paul W. Denton et al.   PLoS Pathogens

Lessons to be Learned from Natural Control of HIV – Future Directions, Therapeutic, and Preventive Implications

(2013) David Shasha et al.   Frontiers in Immunology

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

(2012) M. Klinger et al.   BLOOD

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation

(2012) Liang Shan et al.   IMMUNITY

Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens

(2012) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

Blinatumomab: A historical perspective

(2012) Dirk Nagorsen et al.   PHARMACOLOGY & THERAPEUTICS

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Spinoculation Triggers Dynamic Actin and Cofilin Activity That Facilitates HIV-1 Infection of Transformed and Resting CD4 T Cells

(2011) J. Guo et al.   JOURNAL OF VIROLOGY

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody

(2009) T Osada et al.   BRITISH JOURNAL OF CANCER

Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA

(2009) Ralf Lutterbuese et al.   JOURNAL OF IMMUNOTHERAPY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE